Sacrifice the Bishop

Dendreon COO ousted; staff cut 25% on weak sales of Provenge for prostate cancer

Dendreon Corp. (NASDAQ:DNDN) EVP and COO Hans Bishop took the fall last week for the weak market launch of prostate cancer therapy Provenge sipuleucel-T. Bishop was ousted as part of Dendreon's resulting headcount reduction of about 500, or 25% of employees.

During the product's first year on the market, it appears that

Read the full 514 word article

How to gain access

Continue reading with a
two-week free trial.